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Abstract 16
The anticarcinogenic activity of synthetic 1-O-octadecyl-2,3-dibutyroilglycerol (D-SCAKG) 17
in tumor-cell line of colonocytes (SW620) was performed. The effect of the previously 18
digested D-SCAKG under in vitro intestinal conditions was compared to the bioactivity of 19
non-digested D-SCAKG. Antiproliferative activity of each individual product from digestion 20
(1-O-octadecyl-2-butyroilglycerol; 1-O-octadecyl glycerol; butyric acid) was also performed. 21
The impact of solubilization of lipid products within micellar structures was also tested. 22
The 1-O-octadecyl glycerol was the most active compound, followed by 1-O-octadecyl-2-23
butyroilglycerol, D-SCAKG and butyric acid. The 1-O-octadecyl glycerol and butyric acid 24
were the only molecules that showed antiproliferative effect in absence of micelles. Digested 25
D-SCAKG was 4-fold more effective than non-digested D-SCAKG. A synergism between 1-26
O-octadecyl-2-butyroilglycerol and 1-O-octadecyl glycerol was evidenced.27
As summary, the synthetic D-SCAKG seems to be an interesting antitumoral lipid against 28
colonocytes, especially after previous intestinal digestion, and mainly due to the synergism of 29
the major products, namely 1-O-octadecyl-2-butyroilglycerol and 1-O-octadecyl glycerol. At 30
the same time, 1-O-octadecyl-2-butyroilglycerol would constitute a stable esterified form of 31
butyric acid for its vehiculization. 32
33
Keywords: alkylglycerols, butyric acid, lipid digestion, lipid-delivery pro-drugs, 34
antiproliferative compounds35
36
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1. Introduction36
Alkyglycerols, alkylglycerophospholipids and their derivatives, namely ether lipids, have 37
been the subject of much attention last years because of their special physiological functions38
(Magnusson and Haraldsson, 2011). These glycerides contain O-alkyl or O-alk-1-enyl groups 39
at sn-1 position. Alkylmonoacylglycerols or alkyldiacylglycerols can be also found. Ether 40
lipids are especially abundant as major components of total lipids in liver oil of marine 41
invertebrates and vertebrates, especially shark liver oil. In the human body, they can be found 42
in the cells of the immune system and in human breast milk as membrane components and 43
cellular signaling molecules (Magnusson and Haraldsson, 2011; Torres et al., 2011). As anti-44
tumour agents, they have been related to inhibitory growth, antimetastatic activity, anti-45
neoangiogenic action, and induce differentiation and apoptosis in cancer cells (Brohult et al., 46
1978; Deniau et al., 2011; Krotkiewski et al., 2003; Pedrono et al., 2004; Pedrono et al., 47
2007). Immune stimulation properties have also been attributed to these substances 48
(Braverman and Moser, 2012; Kantah et al., 2012; Mitre et al., 2005). 49
Within ether lipids, one of the most popular is the platelet-activating factor (PAF), a 1-O-50
alkyl-2-acetyl-sn-glycero-3-phosphocholine, with diverse cell mediator effects in a variety of 51
tissues and systems, including circulation, inflammation, development and reproduction 52
(Hanahan, 1986; Prescott et al., 2000). Other important ether lipids are 1-O-alkyl-sn-53
glycerols, which have been also claimed to display various beneficial effects on human health 54
and seems to amplify the production of PAF by incorporation within the PAF precursor, 55
namely the 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine (Himachi et al., 1997; Kantah et 56
al., 2012). On the other hand, 1-O-alkyl-2-acylglycerols are considered of interest as analogs57
of diacylglycerols, which would inhibit protein kinase C. The 1-O-alkyl-2-acylgycerols are 58
produced following cell stimulation after alkylglycerol incorporation in membrane 59
phospholipids. These products bind but do not activates protein kinase C-ε, and compete with 60
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diacylglycerol, which could result in cell growth arrest (Deniau et al., 2011; Heymans et al., 61
1987; Houk et al., 2008; Marigny et al., 2002).  62
Taking into account the attractive properties of these lipids, synthetic ether lipids that do not 63
occur in nature have been prepared to find therapeutic agents (Hartvigsen et al., 2006), such 64
as PAF-like lipids, which retain a short-chain residue at the sn-2 position other than an acetyl 65
group (Tokumura, 1995). In this sense, it has been shown that the shorter the sn-2 chain 66
residue the more active the PAF-like lipid (Kern et al., 1998; Tanaka et al., 1995).67
Recently, Torres et al. (2009 a) synthesized structured alkyldiacylglycerols containing 68
residual short-chain fatty acids at sn-2 and sn-3 locations by enzymatic transesterification of 69
1-O-octadecyl glycerol and ethyl butyrate (1-O-octadecyl-2,3-dibutyroilglycerol; D-SCAKG). 70
Ethyl butyrate was not only chosen by the nature of “short chain residue”, but also on the 71
bioactive importance of butyrate by itself. Besides having physiological role as the main 72
metabolic fuel for colonocytes and control of colonic inflammation, butyrate seems to 73
interfere with the pathogenesis of diverse cancers by inhibiting cell proliferation or inducing 74
apoptosis, such as colorectal cancer, hepatocarcinoma, leukemia, breast and prostate cancer 75
(Avivi-Green et al., 2001; Coradini et al., 1999; Kuefer et al., 2004; Kuroiwa-Trzmielina et 76
al., 2009; Ooi et al., 2009). However, the potential application of butyrate as antitumor agent 77
is limited by the problem to reach enough plasma concentrations required to exert its 78
antiproliferative/differentiating actions. Moreover, it is rapidly metabolized, showing a short 79
half-life (Kuroiwa-Trzmielina et al., 2009; Li et al., 2009). Therefore, there is a current 80
interest on overcoming these drawbacks in order to allow its application as therapeutic agent. 81
Pro-drugs, such tributyrin, have been proposed as alternative of natural butyrate (Clarke et al., 82
2008; Heidor et al., 2012; Kuroiwa-Trzmielina et al., 2009). Torres et al. (2009 a) suggested 83
that the vehiculization of butyric acid by alkylglycerol backbone might be also proposed as 84
interesting butyric pro-drug, due to the double advantage of alkylglycerols as potential lipid 85
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vehicle of butyrate and the own bioactivity of each individual compound, alkylgycerol and 86
butyrate, within the same molecule. 87
Preliminary studies have been performed in order to validate the synthesized D-SCAKG 88
molecule. As first approach, the potential bioaccessibility was assayed by simulating the 89
intestinal digestion of the molecule by pancreatic enzymes under in vitro conditions, since it 90
would be the preliminary step in case of oral intake of this pro-drug (Martin et al., 2011). It 91
was demonstrated that the major hydrolysis product after intestinal digestion of D-SCAKG 92
was the molecule 1-O-octadecyl-2-butyroilglycerol, together with free butyric acid, 1-O-93
octadecyl glycerol and minor non-digested D-SCAKG. Therefore, regardless of the short-94
chain as butyrate, the major digestion product would be the potential bioactive structure under 95
the form of 1-O-alkyl-2-acylglycerol. On the other hand, regardless of the alkylglycerol 96
backbone, the major digestion product 1-O-alkyl-2-butyroilglycerol was a stable esterified 97
form of butyrate. This was considered a positive result since it has been stated that efficient 98
pro-drugs of butyrate should have a sufficiently stable bond between the carrier and butyrate 99
residue to increase its in vivo half-life (Coradini et al., 1999). In fact, in the performed in vitro100
intestinal digestion study, it was shown that the traditional tributyrin proposed as pro-drug of 101
butyrate was completely hydrolyzed to free butyric acid, which would not be the desired 102
situation in case of butyrate pro-drugs. The potential of D-SCAKG as carrier of butyrate was 103
concluded. Furthermore, the additional bioactive ether lipid, namely 1-O-octadecyl glycerol, 104
commonly known as batyl alcohol, was also an interesting product of the in vitro intestinal 105
digestion of the molecule D-SCAKG. Batyl alcohol has been previously tested as anti-tumour 106
lipid (Ando et al., 1972) or antiinflamatory agent (Burford and Gowdey, 1968). Therefore, all 107
the digestion products of the synthetic D-SCAKG after in vitro intestinal lipolisis might be 108
considered attractive products for bioactive properties. 109
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Taking into account all these preliminary data, the aim of the current study was to study a 110
potential anticarcinogenic activity of the synthetic D-SCAKG in tumor-cell line of 111
colonocytes. To perform this study, the digested D-SCAKG under in vitro intestinal 112
conditions was tested, since this last would be the more probable situation in case of oral 113
intake of this molecule, where the hydrolysis products would be the available compounds for 114
intestinal cells. The bioactivities of hydrolysis products of digestion were also tested 115
individually in order to explain the obtained results properly. Furthermore, the impact of 116
solubilization of lipid products within micellar structures of bile salts and phospholipids on 117
bioactivities was also tested, as it would be the most probable situation after in vitro intestinal 118
digestion into the lumen gut environment (Martin et al., 2011). 119
120
2. Materials and methods121
2.1. Reagents and Materials122
The D-SCAKG was synthesized according to a methodology previously described by our 123
group (Torres et al., 2009 a). Trizma, maleic acid, pancreatin, bile salts, phosphatidyl choline 124
from egg yolk, butyric acid and 1-O-octadecyl glycerol were purchased from Sigma-Aldrich 125
Chemie GmbH (Steinheim, Germany). Hydrochloric acid, sodium sulphate anhydrous, 126
sodium chloride, calcium chloride were from Panreac (Barcelona, Spain). N-dodecane for 127
synthesis was purchased from Merck (Darmstadt, Germany). All solvents used were of HPLC 128
grade from Lab-Scan (Dublin, Ireland). Human colon cancer cells (SW620) were obtained 129
from ATCC (Rockville, MD, USA). Dulbecco´s modified Eagle’s medium (DMEM), fetal 130
bovine serum (FBS), glutamine and antibiotic-antimycotic solution were from Gibco BRL 131
(Grand Island, NY, USA).132
133
2.2. In vitro lipid digestion of D-SCAKG134
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The in vitro lipid digestion model was performed according to Martin et al. (2011). Sample (1 135
g) of D-SCAKG was mixed with 0.5 g of bile salts, 0.2 g of lecithin, 5mM CaCl2, 150mM 136
NaCl and 54 mL of 1 M Trizma-maleate buffer pH 7.5. The mixture was homogenized (Ultra-137
Turrax IKA T18) for 20 min at 7000 rpm. The homogenized was placed in a thermostatically 138
controlled vessel (37ºC) under continuous stirring by magnetic stir bar at 1000 rpm. 139
Simulation of intestinal digestion was started by addition of fresh pancreatin extract (1 g of 140
pancreatin in 6 mL of Trizma-maleate buffer pH 7.5 stirred during 10 min and centrifuged at 141
1600 x g during 15 min) and continued up to 60 min. In vitro digestion of each sample was 142
performed in triplicate. 143
The total lipids from samples were extracted by hexane/methyl-tert-butyl ether (50:50, v/v). 144
Furthermore, this medium was acidified by hydrochloric acid (150 mM) in order to stop the 145
enzymatic reaction and to enhance the recovery of butyric acid. n-Dodecane (10 mg) was 146
added as internal standard. The mixture was vortexed for 1 min and centrifuged for 10 min at 147
15,000 rpm. Organic phase containing separated lipids was collected and anhydrous sodium 148
sulfate was added before further analysis. 149
Hydrolysis products were determined according to Torres et al. (2009 b) by gas 150
chromatography (GC) (Hewlett-Packard 5890 series II) with on-column injection using a 7 m 151
5% phenyl methyl silicone capillary column (Quadrex Corporation, New Haven, CT), 0.25 152
µm i.d. A deactivated column of 12 cm 530 µm i.d. was used as pre-column. Injector and 153
detector temperature was 43ºC and 360ºC, respectively. The temperature program was as 154
follows: starting at 40ºC and then heating to 250ºC at 42ºC min-1 with 10 min hold, followed 155
by heating from 250ºC to 325ºC at 7.5ºC min-1 with 30 min hold. Helium was used as carrier 156
gas at a pressure of 5.2 psi. The peaks were computed using GC chemstation software 157
(Agilent Technologies, Santa Clara, CA) and quantified according to the internal standard n-158
dodecane. 159
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The lipid composition of the digested D-SCAKG is shown in Table 1. This composition was 160
subsequently simulated by mixing the individual compounds at the proper proportions 161
according to Table 1 in order to perform the in vitro cell assays. Previously, the individual 162
hydrolysis product 1-O-octadecyl-2-butyroilglycerol (M-SCAKG) from in vitro digestion of 163
D-SCAKG was purified by semi-preparative HPLC, since it cannot be found as commercial 164
standard. The rest of hydrolysis products, namely butyric acid and 1-O-octadecyl glycerol 165
(AKG) were commercial standards.166
167
2.3. In vitro colonocytes assay168
2.3.1. Cell culture169
Human colon cancer cells SW620 were cultured in DMEM supplemented with 10% FBS, 170
2mM glutamine and 1% of antibiotic-antimycotic solution (containing 10,000 units/mL of 171
penicillin base, 10,000 µg/mL of streptomycin base and 25,000 ng/mL of amphotericin B). 172
They were maintained under standard conditions of temperature (37ºC), humidity (95%) and 173
carbon dioxide (5%).174
175
2.3.2. Cell viability assay176
The antiproliferative activity of D-SCAKG and its derivates was measured by MTT (thiazolyl 177
blue tetrazolium bromide) assay. Cells in exponential growth phase were placed in 96-well 178
plates, using 6000 cells per well in a final volume of 200 µL. After 24h incubation, cells were 179
treated by replacing medium with new culture medium (blank wells), medium containing 180
different concentrations of the tested products, or micelles suspensions. Stocks of all 181
treatment compounds, both for mixing directly with DMEM as well as for preparing micelles, 182
were prepared in Ethanol.183
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Cell viability was determined at the same time of treatment and after 48h. To determine the 184
number of viable cells, 20 µL of MTT solution (5 mg/mL in PBS) was added to each well and 185
incubated during 3 h, subsequently the medium was removed and 200 µL of DMSO (dimethyl 186
sulfoxide) was added in order to lyse the cells and resuspend the formazan (MTT metabolic 187
product). Quantities of formazan product, which is directly related to the number of viable 188
cells, were measured at 560 nm using a scanning spectrophometer microplate reader (UVM189
340 Biochrom, Cambridge).  Concentration values corresponding to the parameters IC50190
(50% cell viability inhibition), GI50 (50% growth inhibition), TGI (total growth inhibition) 191
and LC50 (50% cell death)  were calculated according to the NIH definitions using a logistic 192
regression. 193
194
2.3.3. Preparation of Mixed Micellar and Control Solution195
Micelles were prepared with egg yolk lecithin and sodium taurocholate at final concentrations 196
of 150µM and 0.5mM respectively. Micelle solutions were prepared by first adding 197
appropriate amounts of each treatment compounds to a glass vial containing 0.5ml of hexane. 198
For control solutions, a vial with 0.5ml of hexane was prepared. Vials content were dried 199
using a nitrogen evaporator (N-Evap 111, Organomation Associates). Then 0.23 mg of 200
lecithin dissolved in 0.575 mI of hexane was added to each vial and dried again in the same 201
conditions; this was followed by the addition of 500ul of 2mM taurocholate prepared in 202
ethanol and another evaporation step.  Finally, dried content was resuspended in 1ml of 203
DMEM without supplements and mixed with 1ml of complete DMEM, and 200ul of this 204
mixture was added to each well.205
206
3. Results and discussion207
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In order to analyze the potential anticarcinogenic activity of the synthetic D-SCAKG in 208
tumoral colonocytes, the bioactivity of digested D-SCAKG under in vitro intestinal conditions 209
was evaluated. As a first approach, the antiproliferative activity of each individual lipid 210
product (D-SCAKG, M-SCAKG, AKG and butyric acid) was determined as reference. In 211
addition, since the formation of micellar structures might constitute the most usual situation 212
under intestinal digestion into the lumen gut environment (Martin et al., 2011), the impact of 213
solubilization of lipid products within micellar structures of bile salts and phospholipids on 214
the observed bioactivity was also tested, showing a noticeable different when determining the 215
effect of the lipid product under free form (without micellization) or previously solubilized 216
within mixed micelles. 217
As it can be observed in Figure 1, when compounds were added without previous inclusion in 218
micellar structures of bile salts and phospholipids, the AKG and butyric acid were the only 219
molecules that showed a bioactive effect at the assayed concentrations in tumor colonocytes, 220
whereas lack of activity was detected for D-SCAKG and M-SCAKG. Under the free forms, 221
the greatest activity was found for AKG (µM dose range) compared to butyric acid (mM dose 222
range), accordingly with previous studies concerning other alkylglycerols or butyric prodrugs223
(Reynolds et al., 2000; Wächtershäuser and Stein, 2000). Concerning the specific case of 224
AKG, the obtained bioactivity of this compound was not in agreement with the previous study 225
of Deniau et al. (2011), because these authors reported a lack of antitumour effect of the same 226
AKG (1-O-octadecyl glycerol) compared to other individual alkyglycerols. Nevertheless, 227
such study was performed under in vivo conditions in solid grafted tumours in mice after oral 228
administration, and studying the effect on tumour volume, spleen weight, or lung metastases, 229
so the conditions would not be comparable to the present study. On the contrary, Ando et al. 230
(1972) showed a positive anti-tumor activity of batyl alcohol (1-O-octadecyl glycerol) in 231
Ehrlich carcinoma in mice, but such activity was worse than that for alkylglycerols with 232
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shorter alkyl chains. The divergences between our and previous studies show the interest on233
go in depth on the bioactivities of individual alkylglycerols as potential antitumor agents, 234
because such information is scarce.235
When lipid compounds were added under a previous micellization with bile salts and 236
phospholipids, bioactivities were also found for D-SCAKG and M-SCAKG. Again, the best 237
antiproliferative effect was found for AKG, and the bioactivities for D-SCAKG and M-238
SCAKG were found at higher concentrations, being similar between them (Figure 1). Control 239
assays of micelles without inclusion of the experimental compounds showed a lack of effect 240
of such vehicles. 241
With the aim of further evaluating the bioactivity of the different conditions, growth 242
inhibition and promotion of cell death were analyzed by IC50, GI50, TGI and LC50 243
calculation in those conditions in which a bioactive effect was initially observed. As it is 244
shown in Table 2, AKG displayed greater bioactivity than D- and M-SCAKG even without 245
including in micelles. Under micellization, AKG resulted 5-fold more active than the other 246
two lipid compounds (48.3 in cell sensitivity to AKG with respect to 282.02 and 237.04 for 247
D- and M-SCAKG respectively, and 65.38 in citostaticity with respect to 385.28 and 395.09). 248
Regarding cell death, AKG was the only compound displaying an efficient cytotoxic effect at 249
reached concentrations (85.9uM for LC50).250
According to these results, it seems that the potential bioactivity of ether lipids in tumor 251
colonocytes would be different depending on the esterification of the alkylglycerol backbone. 252
Thus, either alkylmonoacylglycerols or alkyldiacylglycerols would be worse antiproliferative 253
agents than non-esterified alkylglycerols. Nevertheless, it should be remarked that 254
alkylmonoacylglycerols would be slightly better than alkyldiacylglycerols, since a value for 255
LC50 was found for the former (M-SCAKG), whereas lack of LC50 dose was detected for 256
alkyldiacylglycerols (D-SCAKG) when they were included under the form of mixed micellar 257
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structures. The observed differences could be related to the own molecular size of the 258
different structures of alkylglycerols. This reason could be also linked to the different 259
solubility and/or polarity of the molecules. Thus, the presence of two hydroxyl groups in the 260
case of AKG compared to the one or two acyl chains of butyrate in the case of M-SCAKG or 261
D-SCAKG, respectively, might lead to better solubility of the AKG molecule in the aqueous 262
media of the cell culture, allowing an easier access to colonocytes. 263
Regardless on the different bioactivities between compounds, the vehiculization of ether 264
lipids within micellar structures enhanced their antiproliferative effects. Thus, whereas lack of 265
activity was observed for D-SCAKG and M-SCAKG after direct addition to the media, a 266
significant antiproliferative effect was observed under micellar solubilization conditions. 267
Accordingly, AKG-mediated inhibition of tumoral cell growth and promotion of cell death 268
were enhanced by micellization. These results would be in agreement with the expected 269
situation at intestinal lumen, where most lipid compounds need the support of mixed micelles 270
to be dispersed in the aqueous media to cross the unstirred water layer close to enterocytes 271
previous to absorption (Christensen et al., 1995; Ramirez et al., 2001). At this respect, the 272
non-esterified form of AKG might allow an easier formation of mixed micelles compared to 273
D-SCAKG and M-SCAKG due to the availability of the two hydroxyl groups of the 274
molecule, which confers emulgent-like properties, allowing its dispersion into mixed micelles 275
and in turn the accessibility to colonocytes. 276
The obtained results contributed to the knowledge of the bioactivity of ether lipids, because to 277
the best of our knowledge, previous studies showing differences between non-esterified and 278
esterified alkyglycerols as antiproliferative agents by in vitro tumor-cell models have not been 279
found. Furthermore, the effect of micellization on the efficacy of these compounds on 280
intestinal cells has not been previously reported. 281
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Nevertheless, it is important to remark that the results found for esterified forms of AKG 282
might be considered an artifact in the particular case of an oral intake of D-SCAKG. This is 283
because, as most esterified lipids, these are partially hydrolyzed at intestinal tract by digestive 284
lipases. Subsequently, the hydrolysis products are those major included in mixed micelles of 285
bile salts and phospholipids to allow their access to intestinal cells. In fact, according to Table 286
1 and in agreement to Martin et al (2011), the simulation of intestinal digestion of D-SCAKG 287
produced a stable form of esterified butyric acid as 1-O-octadecyl-2-butyroilglycerol (M-288
SCAKG) as major hydrolysis product (> 50%). Free AKG (> 20%) and free butyric acid 289
(20%) were also released as bioactive compounds of interest, together with minor residual D-290
SCAKG. Due to that, it was approached that the bioactivity of this mixture of compounds 291
solubilized in micellar structures, namely M-SCAKG, AKG, butyric acid and residual D-292
SCAKG, should be tested for validate the bioactivity of the synthetic D-SCAKG in tumor 293
colonocytes, in order to simulate the potential situation after oral intake of this lipid.294
The bioactivity of digested D-SCAKG compared to that of non-digested D-SCAKG in shown 295
in Figure 2. Furthermore, both compounds were also compared in terms of growth inhibition, 296
citostaticity and citotoxicity in Table 3.a. In addition, data for each individual component of 297
the mixture according to the pro ortions of Table 1 was estimated (Table 3.b). As it is shown 298
in Figure 2 and Table 3.a, the digested D-SCAKG was around 4-fold more effective than the 299
former non-digested D-SCAKG. Therefore, this result suggests that the digestion of D-300
SCAKG would improve efficiency on its antiproliferative activity of this synthetic lipid after 301
oral intake. Of note, taking into account the dose of each individual compound in the mixture 302
of hydrolysis products (Table 3.b), much lower effective concentrations were found for all 303
compounds when they were mixed (Table 3.b) than when they were tested individually (Table 304
2).  Especially attractive was the finding that the bioactivity of AKG, the most effective 305
compound individually, was greater when this compound was added together with D-306
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SCAKG, M-SCAKG and butyric acid. Thus, 86 µM of AKG was necessary to reach the 307
LC50 value when it was added individually to cells (Table 2), whereas such value was 308
reduced by three times (26 µM LC50) when AKG was included in the micellized media 309
together with the rest of hydrolysis compounds (Table 3.b). Similarly, IC50, GI50 and TGI 310
reduced by twice. Taking into account that AKG was only present in the digested mixture at 311
around 20% of total lipids (Table 1), whereas it was 100% when added individually, these 312
results suggest a potential synergism between the hydrolysis products, promoting the efficacy 313
of the individual compounds and in turn the total efficacy of the mixture.314
In order to study the interaction of compounds further additional experiments were performed 315
by the combination of the lipid products at the same proportion that obtained after in vitro316
digestion, except that butyric acid was not added to the media. This lead to a lipid mixture 317
mainly formed by the major hydrolysis products M-SCAKG  and AKG (68 and 29 g/100 g 318
total lipids, respectively) . As shown in Figure 3, the combination of M-SCAKG and AKG 319
showed almost the same results as found for the combination of all compounds, suggesting 320
that the active compounds of the digested D-SCAKG were its major hydrolysis products, 321
namely M-SCAKG and AKG. Furthermore, this result confirmed a synergism between M-322
SCAKG and AKG, since the antiproliferative dose of both compounds in the mixture was 323
lower than the dose needed for each individual compounds separately (Table 3.b and Table 2). 324
These results suggest two promising activities for the major hydrolysis product of D-SCAKG 325
after in vitro intestinal digestion, namely M-SCAKG. On one hand, it would contribute 326
together with AKG to a potential antitumoral activity against tumor colonocytes, and, on the 327
other hand, M-SCAKG would constitute a stable esterified form of butyric acid for its 328
vehiculization. This is because efficient pro-drugs of butyrate should have a sufficiently stable 329
bond between the carrier and butyrate residue to increase its in vivo half-life (Coradini et al., 330
1999).331
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Additional studies might be conducted to further explain the mechanism of synergism 332
between M-SCAKG and AKG. At this respect, concerning shark liver oil as the main natural 333
source of alkylglycerols, it has been suggested that the bioactivity of such oil might be likely 334
mediated by the presence of alkylglycerols (Pedrono et al., 2004), but the interaction with 335
other lipid species in the oil (free alkylglycerols, mono- and di-esterified alkylglycerols with 336
different fatty acids, and acylglycerols) could not be rejected. One explanation of the observed 337
results of synergism might be related to the formation of micellar structures, both in the 338
number or size of micelles. This is because in general, it has been shown that higher surface, 339
extension and swelling of micelles with hydrolysis products enhance the inclusion of the rest 340
of lipophilic compounds, and in turns their bioaccessibility (Porter and Charman, 2001). 341
Similarly, it might be possible that the combination of M-SCAKG and AKG led to the 342
formation of higher number and/or surface of micellar structures, compared to the sole 343
presence of each individual component, allowing the access to colonocytes. According to this 344
approach, further studies were performed by counting the number of micellar structures by 345
light microscope from micelles preparations of AKG, M-SCAKG or their combination. 346
However, no conclusive results were found (data not shown). 347
On the other hand, it would be also interesting to elucidate whether the observed responses 348
might be also related to a synergistic action of M-SCAKG and AKG on the own colonocytes 349
once the compounds were absorbed. In this regard is important to remark that the M-SCAKG 350
molecule showed the typical structure of those analogues of diacylglycerols, namely 1-O-351
alkyl-2-acylglycerols, which have been pointed out as inhibitors of protein kinase C (Deniau 352
et al., 2011; Marigny et al., 2002; Heymans et al., 1987). Additionally, once inside the 353
enterocite the own forms of alkylglycerols would be derived to other diverse bioactive forms 354
under the fast dynamic of lipid remodeling, leading to alternate fatty acids at sn-2 location 355
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different to butyric acid, via the deacylation-reacylation pathway of the Lands’s cycle (Perez 356
et al., 2006). 357
In summary, the synthetic D-SCAKG seems to be an interesting antitumoral lipid against 358
colonocytes, especially after previous intestinal digestion, after solubilization in mixed 359
micelles, and mainly due to the synergism of the major products, namely 1-O-octadecyl-2-360
butyroilglycerol and 1-O-octadecyl glycerol. At the same time, 1-O-octadecyl-2-361
butyroilglycerol would constitute a stable esterified form of butyric acid for its vehiculization.362
The current study also showed the importance of considering the digestive hydrolysis process 363
of lipid compounds on the evaluation of bioactivities at intestinal level, as well as the 364
importance of vehiculize the lipid products as it would be at intestinal lumen, namely under 365
the form of mixed micelles. Nevertheless, further studies would be necessary in order to 366
explain the observed effects related to the intracellular metabolism once the lipid compounds 367
were absorbed.368
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Figure captions479
480
Figure 1. Antiproliferative effect of free and  micellized form of the different lipid 481
compounds. Bioactivity was determined on sw620 human colon cancer cells by the MTT 482
(thiazolyl blue tetrazolium bromide) assay. Butyric acid (d) was not included in the study of 483
micellization since it is solubilized in the aqueous media. Data represent the mean +/- s.e.m.of 484
at least 2 independent experiments, each performed in quadruplicate. AKG, 1-O-octadecyl 485
glycerol; D-SCAKG, 1-octadecyl-2,3-dibutyroilglycerol; M-SCAKG, 1-O-octadecyl-2-486
butyroilglycerol. 487
488
Figure 2. Antiproliferative effect of digested D-SCAKG on sw620 human colon cancer 489
cells. To test this compound, D-SCAKG, M-SCAKG, AKG and butyric acid were combined 490
at the same proportion that obtained after in vitro digestion. AKG and their esterified forms 491
were included in micelles, and butyric acid was added after micelle resuspension in culture 492
medium. Data represents the mean +/- s.e.m.of at least 2 independent experiments each 493
performed in quadruplicate. For comparative reasons, data are expressed at molar 494
concentration of D-SCAKG equivalent. It the case of digested D-SCAKG equivalents, they 495
were estimated from the weight of lipid mixture of hydrolysis products, which corresponded 496
to a weight of non-digested D-SCAKG and, in turn to a specific molar concentration of D-497
SCAKG. 498
AKG, 1-O-octadecyl glycerol; D-SCAKG, 1-octadecyl-2,3-dibutyroilglycerol; M-SCAKG, 1-499
O-octadecyl-2-butyroilglycerol500
501
Figure 3. Comparision of antiproliferative effect of digested D-SCAKG with a 502
preparation in which butyric is excluded. M-SCAKG and AKG constitute the 97% of total503
composition. All hydrolisis products were combined at the same proportion that obtained after 504
in vitro digestion. AKG and their esterified forms were included in micelles, while butyric 505
acid (when used) was added after micelle resuspension in culture medium. Data represent the 506
mean +/- s.e.m.of at least 2 independent experiments each performed in quadruplicate. For 507
comparative reasons, data are expressed at molar concentration of D-SCAKG equivalent, as 508
explained in figure 2.509
AKG, 1-O-octadecyl glycerol; D-SCAKG, 1-octadecyl-2,3-dibutyroilglycerol; M-SCAKG, 1-510
O-octadecyl-2-butyroilglycerol511
512
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512
Table 1. Lipid composition of digested D-SCAKG by in vitro intestinal model
g/100 g total lipids
D-SCAKGa 2.2
M-SCAKGb 54.4
AKGc 23.4
Butyric acid 20.0
a D-SCAKG (1-octadecyl-2,3-dibutyroilglycerol); b M-SCAKG (1-O-octadecyl-2-
butyroilglycerol); c AKG (1-O-octadecyl glycerol)
513
514
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Table 2. IC50, GI50, TGI and LC50 parameters of the esterified forms of AKG, as well as non-514
esterified AKG and butyric acid. These parameters were calculated from the results obtained in 515
viability assays according to the NIH definitions using a logistic regression. Values are represented as 516
the mean+/- s.e.m. of at least 2 independent experiments each performed in quadruplicate. NLO: No 517
Lethality Observed.518
519
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521
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Table 3. IC50, GI50, TGI and LC50 parameters of digested AKG on sw620 human colon cancer cells.  524
(a) Digested media versus non-digested media. Values were calculated as mean values +/- s.e.m. of at525
least 2 independent experiments each performed in quadruplicate. For comparative reasons, data are 526
expressed at molar concentration of D-SCAKG equivalent. In the case of digested D-SCAKG 527
equivalents, they were estimated from the weight of lipid mixture of hydrolysis products, which 528
corresponded to a weight of non-digested D-SCAKG and, in turn to a specific molar concentration of 529
D-SCAKG. (b) Calculated IC50, GI50, TGI and LC50 for each product of digestion taking into 530
account their respective proportion in the mixture of digested D-SCAKG.   531
532
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Figure 1535
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Figure 2555
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Figure 3561
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Highlights571
Intestinal digestion of alkylglycerols diesterified with butyric acid was simulated.572
The antitumor effect of digested alkylglycerol was performed in tumor colonocites. 573
Digested alkylglycerol was 4-fold more effective than the non-digested one. 574
Synergism between major digestion products was found. 575
Diesterified alkylglycerol would be a stable lipid for vehiculization of butyric acid.576
577
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